Compare · BIOA vs NVO
BIOA vs NVO
Side-by-side comparison of BioAge Labs Inc. (BIOA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, BIOA is up 289.7% and NVO is down 34.2% - BIOA leads by 323.9 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 13 for BIOA).
- Company
- BioAge Labs Inc.
- Novo Nordisk A/S
- Price
- $17.03-1.25%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- +3.94%
- +13.32%
- 1Y return
- +289.70%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 5
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BIOA
- Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 11% to 36,575 units (SEC Form 4)
- SEC Form DEFA14A filed by BioAge Labs Inc.
- SEC Form DEF 14A filed by BioAge Labs Inc.
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
- BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Rubin Paul D
- SEC Form 144 filed by BioAge Labs Inc.
- Needham initiated coverage on BioAge Labs with a new price target
- SEC Form S-3ASR filed by BioAge Labs Inc.
- SEC Form S-8 filed by BioAge Labs Inc.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S